SeraCare Life Sciences (SRLS) says it will explore and evaluate potential strategic alternatives...
SeraCare Life Sciences (SRLS) says it will explore and evaluate potential strategic alternatives to enhance shareholder value, including a sale or other transaction, but there is no set timetable for making a decision. SRLS +3.3% premarket. (PR)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs